Cynata Reviews Future Path After Phase 3 Osteoarthritis Trial Results
Cynata Therapeutics Limited (ASX: CYP) has announced the top-line results from the Phase 3 SCUlpTOR trial evaluating CYP-004 for the treatment of knee osteoarthritis. The trial confirmed that CYP-004 was generally well tolerated, with safety outcomes closely matching those observed in the placebo arm. Despite this, the study did not deliver the targeted clinical endpoints.
The proportion of participants reaching the patient-acceptable symptom state for knee pain after 24 months was similar between both groups, while cartilage thickness outcomes also showed no statistically significant difference. Although participants receiving CYP-004 experienced a meaningful and sustained reduction in knee pain over the study period, comparable improvements were observed in the placebo arm, limiting the ability to demonstrate a treatment advantage.
Following these findings, and in conjunction with recently reported outcomes from another clinical program, the company has commenced a strategic review of development opportunities for its proprietary Cymerus™ cell therapy platform. Management stated that while the results were disappointing, the trial generated valuable clinical insights and confirmed the product’s safety profile. Cynata intends to provide further updates regarding the future direction of its technology platform as the review progresses.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Cynata Reviews Future Path After Phase 3 Osteoarthritis Trial Results
Cynata Therapeutics Limited (ASX: CYP) has announced the top-line results from the Phase 3 SCUlpTOR trial evaluating CYP-004 for the treatment of knee osteoarthritis. The trial confirmed that CYP-004 was generally well tolerated, with safety outcomes closely matching those observed in the placebo arm. Despite this, the study did not deliver the targeted clinical endpoints.
The proportion of participants reaching the patient-acceptable symptom state for knee pain after 24 months was similar between both groups, while cartilage thickness outcomes also showed no statistically significant difference. Although participants receiving CYP-004 experienced a meaningful and sustained reduction in knee pain over the study period, comparable improvements were observed in the placebo arm, limiting the ability to demonstrate a treatment advantage.
Following these findings, and in conjunction with recently reported outcomes from another clinical program, the company has commenced a strategic review of development opportunities for its proprietary Cymerus™ cell therapy platform. Management stated that while the results were disappointing, the trial generated valuable clinical insights and confirmed the product’s safety profile. Cynata intends to provide further updates regarding the future direction of its technology platform as the review progresses.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au